It is approved by the fda in combination with cisplatin (another chemotherapy drug) for the initial treatment of advanced nonsquamous non-small cell lung cancer (nsclc), a specific type of nsclc. it is not indicated for patients who have a different type of nsclc called squamous cell.it is approved by the fda for the treatment of patients with advanced nonsquamous non-small cell lung cancer (nsclc), a specific type of nsclc, to maintain the effect of initial treatment with chemotherapy and whose disease has not worsened. it is not indicated for patients who have a different type of nsclc called squamous cell.it is approved by the fda as a single agent (used alone) for the treatment of patients with advanced nonsquamous non-small cell lung cancer (nsclc), a specific type of nsclc, after prior chemotherapy. it is not indicated for patients who have a different type of nsclc called squamous cell. it is a treatment for malignant pleural mesothelioma.dose: once every 21 days.